Key result
Streptozotocin-induced diabetic cardiomyopathy in mice resulted in a 63% decrease in myocardial GHSR1a expression, which significantly correlated with impaired glucose tolerance.
Why the study?
Does streptozotocin-induced diabetic cardiomyopathy alter myocardial GHSR1a expression in mice?
Does streptozotocin-induced diabetic cardiomyopathy alter myocardial GHSR1a expression in mice?
Effect estimate: 63% decrease
p-value: p=0.0042
The subclinical stage of diabetic cardiomyopathy in mice is accompanied by a significant decrease in myocardial GHSR1a, which correlates with impaired contractility markers, suggesting its potential as a biomarker.
GHSR1a downregulation may mark early murine diabetic cardiomyopathy; leaves open biomarker utility pending human validation.
Ghrelin and its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), are present in cardiac tissue. Activation of GHSR1a by ghrelin promotes cardiomyocyte contractility and survival, and changes in myocardial GHSR1a and circulating ghrelin track with end-stage heart failure, leading to the hypothesis that GHSR1a is a biomarker for heart failure. We hypothesized that GHSR1a could also be a biomarker for diabetic cardiomyopathy (DCM). We used two models of streptozotocin (STZ)-induced DCM: group 1, adult mice treated with 35 mg/kg STZ for 3 days; and group 2, neonatal mice treated with 70 mg/kg STZ at days 2 and 5 after birth. In group 1, mild fasting hyperglycemia (11 mM) was first detected 8 weeks after the last injection, and in group 2, severe fasting hyperglycemia (20 mM) was first detected 1 to 3 weeks after the last injection. In group 1, left ventricular function was slightly impaired as measured by echocardiography, and Western blot analysis showed a significant decrease in myocardial GHSR1a. In group 2, GHSR1a levels were also decreased as assessed by Cy5-ghrelin(1–19) fluorescence microscopy, and there was a significant negative correlation between GHSR1a levels and glucose tolerance. There were significant positive correlations between GHSR1a and ghrelin and between GHSR1a and sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), a marker for contractility, but not between GHSR1a and B-type natriuretic peptide, a marker for heart failure. We conclude that the subclinical stage of DCM is accompanied by alterations in the myocardial ghrelin-GHSR1a system, suggesting the possibility of a biomarker for DCM.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2017) studied Diabetic cardiomyopathy (n=26). Streptozotocin (STZ) vs. Vehicle control was evaluated on Myocardial GHSR1a expression (63% decrease, p=0.0042). Streptozotocin-induced diabetic cardiomyopathy in mice resulted in a 63% decrease in myocardial GHSR1a expression, which significantly correlated with impaired glucose tolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: